This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Danielsson, P. Articles by Marcus, C. Search for Related Content PubMed PubMed Citation Articles by Danielsson, P. Articles by Marcus, C. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology Obesity

Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes

Department of Paediatrics, Clintec, and the National Childhood Obesity Centre, Karolinska Institutet, Karolinska University Hospital, S-141 86 Stockholm, Sweden

Address all correspondence and requests for reprints to: Professor Claude Marcus, Department of Pediatrics and the National Childhood Obesity Centre, B57, Karolinska University Hospital, Huddinge, S-141 86 Stockholm, Sweden. E-mail: claude.marcus{at}ki.se.

Objective: Behavioral treatment of children suffering from hypothalamic obesity or uncomplicated obesity in combination with syndromes that aggravate this condition has proven to be ineffective. The combination of comorbidities and severe obesity lower the quality of these children’s lives drastically. The present goal was to determine whether treatment with sibutramine has a beneficial effect on such children.

Design and Subjects: A double-blind, placebo-controlled, cross-over study (20 + 20 wk), followed by a 6-month open phase, was performed. The primary indicator of efficacy was the body mass index (BMI) SD score (SDS) value, which was analyzed using an ANOVA repeated-measures design [intention to treat (ITT)]. The 50 children (7–20 yr of age) involved included 22 with hypothalamic obesity and 28 with uncomplicated obesity plus aggravating syndromes. Forty-five patients completed the first phase, and 42 participated in the entire study.

Results: The group that initially received the placebo demonstrated an insignificant decrease (–0.06) in BMI SDS during this treatment but a significant decrease (–0.68; P < 0.001) when treated with sibutramine. The other group demonstrated a reduction in their BMI SDS of –0.72 during administration of sibutramine and a rebound of +0.43 when placed on the placebo (P < 0.001 in both cases). The response of children with hypothalamic obesity was also significant but was less pronounced than that of children with nonhypothalamic obesity. During the open phase, a continuous reduction in weight was observed. The treatment was tolerated well.

Conclusion: The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial.

This article has been cited by other articles:

				H. Gleeson, R. Amin, and M. Maghnie 'Do no harm': management of craniopharyngioma Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S95 - S99. [Abstract] [Full Text] [PDF]